表紙:経口バイオ医薬品・バイオシミラーの世界市場(2022年)
市場調査レポート
商品コード
1062909

経口バイオ医薬品・バイオシミラーの世界市場(2022年)

Oral Biologics & Biosimilar Drugs Global Market Report 2022

出版日: 受注後作成 | 発行: The Business Research Company | ページ情報: 英文 300 Pages | 納期: 2~10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=137.31円
経口バイオ医薬品・バイオシミラーの世界市場(2022年)
出版日: 受注後作成
発行: The Business Research Company
ページ情報: 英文 300 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の経口バイオ医薬品・バイオシミラー市場について調査し、市場規模や予測、市場力学、セグメント・地域別の市場分析、競合情勢、戦略、主要企業のプロファイル等の情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 経口バイオ医薬品・バイオシミラーの市場特性

第3章 経口バイオ医薬品・バイオシミラーの市場動向と戦略

第4章 経口バイオ医薬品・バイオシミラーに対するCOVID-19の影響

第5章 経口バイオ医薬品・バイオシミラーの市場規模と成長

  • 市場実績(金額)
    • 市場促進要因
    • 市場抑制要因
  • 市場予測(金額)
    • 市場促進要因
    • 市場抑制要因

第6章 経口バイオ医薬品・バイオシミラー市場のセグメンテーション

  • 市場実績と予測(金額):治療別
  • リンパ球モジュレーター
  • インターロイキン阻害剤
  • 腫瘍壊死因子-アルファ阻害剤
  • 市場実績と予測(金額):疾患別
  • 喘息
  • クローン病
  • がん腫
  • 関節炎
  • 糖尿病
  • 多発性骨髄腫
  • 腸炎
  • 多発性硬化症
  • 肉腫
  • 乾癬・その他
  • 市場実績と予測(金額):分子タイプ別
  • ワクチン
  • タンパク質・ペプチド
  • モノクローナル抗体
  • その他
  • 市場実績と予測(金額):流通チャネル別
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 経口バイオ医薬品・バイオシミラー市場の地域・国分析

  • 市場実績と予測(金額):地域別
  • 市場実績と予測(金額):国別

第8章 アジア太平洋の経口バイオ医薬品・バイオシミラー市場

  • 市場概要
  • 地域情報、COVID-19の影響、市場情報、背景情報、政府のイニシアチブ、規制、規制機関、主要な協会、徴収される税金、法人税の構造、投資、主要企業
  • 市場実績と予測(金額):治療別

第9章 中国の経口バイオ医薬品・バイオシミラー市場

  • 市場概要
  • 市場実績と予測(金額):治療別

第10章 インドの経口バイオ医薬品・バイオシミラー市場

  • 市場実績と予測(金額):治療別

第11章 日本の経口バイオ医薬品・バイオシミラー市場

  • 市場実績と予測(金額):治療別

第12章 オーストラリアの経口バイオ医薬品・バイオシミラー市場

  • 市場実績と予測(金額):治療別

第13章 インドネシアの経口バイオ医薬品・バイオシミラー市場

  • 市場実績と予測(金額):治療別

第14章 韓国の経口バイオ医薬品・バイオシミラー市場

  • 市場実績と予測(金額):治療別

第15章 西欧の経口バイオ医薬品・バイオシミラー市場

  • 市場概要
  • 市場実績と予測(金額):治療別

第16章 英国の経口バイオ医薬品・バイオシミラー市場

  • 市場実績と予測(金額):治療別

第17章 ドイツの経口バイオ医薬品・バイオシミラー市場

  • 市場実績と予測(金額):治療別

第18章 フランスの経口バイオ医薬品・バイオシミラー市場

  • 市場実績と予測(金額):治療別

第19章 東欧の経口バイオ医薬品・バイオシミラー市場

  • 市場概要
  • 市場実績と予測(金額):治療別

第20章 ロシアの経口バイオ医薬品・バイオシミラー市場

  • 市場実績と予測(金額):治療別

第21章 北米の経口バイオ医薬品・バイオシミラー市場

  • 市場概要
  • 市場実績と予測(金額):治療別

第22章 米国の経口バイオ医薬品・バイオシミラー市場

  • 市場概要
  • 市場実績と予測(金額):治療別

第23章 南米の経口バイオ医薬品・バイオシミラー市場

  • 市場概要
  • 市場実績と予測(金額):治療別

第24章 ブラジルの経口バイオ医薬品・バイオシミラー市場

  • 市場実績と予測(金額):治療別

第25章 中東の経口バイオ医薬品・バイオシミラー市場

  • 市場概要
  • 市場実績と予測(金額):治療別

第26章 アフリカの経口バイオ医薬品・バイオシミラー市場

  • 市場概要
  • 市場実績と予測(金額):治療別

第27章 経口バイオ医薬品・バイオシミラー市場の競合情勢と企業プロファイル

  • 市場の競合情勢
  • 市場の企業プロファイル
    • Novartis
    • Rani Therapeutics
    • Eli Lilly and Co.
    • AstraZeneca plc
    • Novo Nordisk A/S

第28章 経口バイオ医薬品・バイオシミラーのパイプライン分析

第29章 経口バイオ医薬品・バイオシミラー市場における主要な合併および買収

第30章 経口バイオ医薬品・バイオシミラー市場の将来展望と潜在的分析

第31章 付録

目次
Product Code: h1131

“Oral Biologics & Biosimilar Drugs Implants Global Market Report 2022” from The Business Research Company provides the strategists, marketers and senior management with the critical information they need to assess the global oral biologics & biosimilars market.

This report focuses on oral biologics & biosimilars market which is experiencing strong growth. The report gives a guide to the oral biologics & biosimilars market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Where is the largest and fastest growing market for the oral biologics & biosimilars market? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The Oral Biologics & Biosimilars Market market global report” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider oral biologics & biosimilars market market, and compares it with other markets.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the Covid 19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of Covid 19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The oral biologics & biosimilars market market section of the report gives context. It compares the oral biologics & biosimilars market market with other segments of the oral biologics & biosimilars market market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, oral biologics & biosimilars market indicators comparison.

Scope

Markets Covered:

1) By Therapy: Lymphocyte Modulators; Interleukin Inhibitors; Tumor Necrosis Factor-Alpha Inhibitors

2) By Disease: Asthma; Crohn'S Disease; Carcinoma; Arthritis; Diabetes; Multiple Myeloma; Enterocolitis; Multiple Sclerosis; Sarcoma; Psoriasis and Others

3) By Molecule Type: Vaccines; Proteins & Peptides; Monoclonal Antibodies; Others

4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Companies Mentioned: Novartis; Rani Therapeutics; Eli Lilly and Co.; AstraZeneca plc; Novo Nordisk A/S

Countries: Brazil; China; France; Germany; India; Indonesia; Japan; South Korea; Russia; UK; USA; Australia

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, per capita expenditure.

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

1. Executive Summary

2. Oral Biologics & Biosimilars Market Characteristics

3. Oral Biologics & Biosimilars Market Trends And Strategies

4. Impact Of COVID-19 On Oral Biologics & Biosimilars

5. Oral Biologics & Biosimilars Market Size And Growth

  • 5.1. Global Oral Biologics & Biosimilars Historic Market, 2016-2021, $ Billion
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints On The Market
  • 5.2. Global Oral Biologics & Biosimilars Forecast Market, 2021-2026F, 2031F, $ Billion
    • 5.2.1. Drivers Of The Market
    • 5.2.2. Restraints On the Market

6. Oral Biologics & Biosimilars Market Segmentation

  • 6.1. Global Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Lymphocyte Modulators
  • Interleukin Inhibitors
  • Tumor Necrosis Factor-Alpha Inhibitors
  • 6.2. Global Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Asthma
  • Crohn'S Disease
  • Carcinoma
  • Arthritis
  • Diabetes
  • Multiple Myeloma
  • Enterocolitis
  • Multiple Sclerosis
  • Sarcoma
  • Psoriasis and Others
  • 6.3. Global Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Vaccines
  • Proteins & Peptides
  • Monoclonal Antibodies
  • Others
  • 6.4. Global Oral Biologics & Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

7. Oral Biologics & Biosimilars Market Regional And Country Analysis

  • 7.1. Global Oral Biologics & Biosimilars Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 7.2. Global Oral Biologics & Biosimilars Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

8. Asia-Pacific Oral Biologics & Biosimilars Market

  • 8.1. Asia-Pacific Oral Biologics & Biosimilars Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

9. China Oral Biologics & Biosimilars Market

  • 9.1. China Oral Biologics & Biosimilars Market Overview
  • 9.2. China Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

10. India Oral Biologics & Biosimilars Market

  • 10.1. India Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

11. Japan Oral Biologics & Biosimilars Market

  • 11.1. Japan Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

12. Australia Oral Biologics & Biosimilars Market

  • 12.1. Australia Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

13. Indonesia Oral Biologics & Biosimilars Market

  • 13.1. Indonesia Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

14. South Korea Oral Biologics & Biosimilars Market

  • 14.1. South Korea Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

15. Western Europe Oral Biologics & Biosimilars Market

  • 15.1. Western Europe Oral Biologics & Biosimilars Market Overview
  • 15.2. Western Europe Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

16. UK Oral Biologics & Biosimilars Market

  • 16.1. UK Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

17. Germany Oral Biologics & Biosimilars Market

  • 17.1. Germany Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

18. France Oral Biologics & Biosimilars Market

  • 18.3. France Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

19. Eastern Europe Oral Biologics & Biosimilars Market

  • 19.1. Eastern Europe Oral Biologics & Biosimilars Market Overview
  • 19.2. Eastern Europe Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

20. Russia Oral Biologics & Biosimilars Market

  • 20.1. Russia Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

21. North America Oral Biologics & Biosimilars Market

  • 21.1. North America Oral Biologics & Biosimilars Market Overview
  • 21.2. North America Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

22. USA Oral Biologics & Biosimilars Market

  • 22.1. USA Oral Biologics & Biosimilars Market Overview
  • 22.2. USA Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

23. South America Oral Biologics & Biosimilars Market

  • 23.1. South America Oral Biologics & Biosimilars Market Overview
  • 23.2. South America Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

24. Brazil Oral Biologics & Biosimilars Market

  • 24.1. Brazil Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

25. Middle East Oral Biologics & Biosimilars Market

  • 25.1. Middle East Oral Biologics & Biosimilars Market Overview
  • 25.2. Middle East Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

26. Africa Oral Biologics & Biosimilars Market

  • 26.1. Africa Oral Biologics & Biosimilars Market Overview
  • 26.2. Africa Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

27. Oral Biologics & Biosimilars Market Competitive Landscape And Company Profiles

  • 27.1. Oral Biologics & Biosimilars Market Competitive Landscape
  • 27.2. Oral Biologics & Biosimilars Market Company Profiles
    • 27.2.1. Novartis
      • 27.2.1.1. Overview
      • 27.2.1.2. Products and Services
      • 27.2.1.3. Strategy
      • 27.2.1.4. Financial Performance
    • 27.2.2. Rani Therapeutics
      • 27.2.2.1. Overview
      • 27.2.2.2. Products and Services
      • 27.2.2.3. Strategy
      • 27.2.2.4. Financial Performance
    • 27.2.3. Eli Lilly and Co.
      • 27.2.3.1. Overview
      • 27.2.3.2. Products and Services
      • 27.2.3.3. Strategy
      • 27.2.3.4. Financial Performance
    • 27.2.4. AstraZeneca plc
      • 27.2.4.1. Overview
      • 27.2.4.2. Products and Services
      • 27.2.4.3. Strategy
      • 27.2.4.4. Financial Performance
    • 27.2.5. Novo Nordisk A/S
      • 27.2.5.1. Overview
      • 27.2.5.2. Products and Services
      • 27.2.5.3. Strategy
      • 27.2.5.4. Financial Performance

28. Oral Biologics & Biosimilars Pipeline Analysis

29. Key Mergers And Acquisitions In The Oral Biologics & Biosimilars Market

30. Oral Biologics & Biosimilars Market Future Outlook and Potential Analysis

31. Appendix

  • 31.1. Abbreviations
  • 31.2. Currencies
  • 31.3. Research Inquiries
  • 31.4. The Business Research Company
  • 31.5. Copyright And Disclaimer